Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury

Nature Medicine
J J RadeD A Dichek

Abstract

Catalytically active thrombin, acting locally, is thought to mediate neointima formation after arterial injury. We constructed an adenovirus vector, AdHV-1.2, containing a complementary DNA for the thrombin inhibitor hirudin. AdHV-1.2 directed the synthesis and secretion of biologically active hirudin from vascular cells in vitro. In vivo gene transfer of hirudin into smooth muscle cells of injured rat carotid arteries resulted in peak secretion of at least 34+/-23 pg hirudin per vessel per 24 hours, and resulted in a significant (P<0.05) 35% reduction in neointima formation. Systemic partial thromboplastin times were not affected by local hirudin expression. These results support the hypothesis that local thrombin activity contributes to neointima formation after arterial injury and suggest that local delivery of a highly specific antithrombin may constitute an effective intervention for arterial proliferative disease.

References

Oct 1, 1992·The Journal of Clinical Investigation·N A NelkenS R Coughlin
Jan 1, 1991·Haemostasis·M SpannaglW Schramm
Jan 30, 1992·The New England Journal of Medicine·V FusterJ H Chesebro
Apr 1, 1991·Seminars in Thrombosis and Hemostasis·P Walsmann
Feb 1, 1991·Australian and New Zealand Journal of Medicine·J A Savige, C M Lockwood
Feb 1, 1991·Australian and New Zealand Journal of Medicine·D M Paton
Feb 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·H E von der LeyenV J Dzau
Sep 1, 1995·Circulation Research·A H SchulickD A Dichek
Oct 25, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J GuzmanT Finkel
Jan 1, 1991·Methods in Molecular Biology·F L Graham, L Prevec

❮ Previous
Next ❯

Citations

Dec 13, 2005·Annals of Biomedical Engineering·Kwangdeok LeeMarc S Penn
Dec 21, 2000·Current Atherosclerosis Reports·T Pakkanen, S Ylä-Herttuala
May 18, 2004·Pathologie-biologie·M MazighiL J Feldman
Feb 16, 2000·Lancet·S Ylä-Herttuala, J F Martin
Jun 29, 2000·Trends in Pharmacological Sciences·H Bult
Apr 28, 2001·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·E TeigerS Adnot
Aug 8, 1998·The International Journal of Biochemistry & Cell Biology·N R GoldsackG J Laurent
Oct 27, 2001·Acta Physiologica Scandinavica·R C Smith, K Walsh
Jul 8, 1999·Human Gene Therapy·M B DeYoungD A Dichek
May 15, 1998·Human Gene Therapy·D B SchneiderR L Geary
Jan 1, 1997·Fundamental & Clinical Pharmacology·D Stephan, E G Nabel
Aug 28, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Ravisekhar GadepalliGadiparthi N Rao
Jul 12, 2002·Drugs·Juha RutanenSeppo Ylä-Herttuala
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·M KesterM Kozak
Dec 10, 1999·The Annals of Thoracic Surgery·D K DasD W Deaton
Mar 29, 2001·Proceedings of the National Academy of Sciences of the United States of America·P ZoldhelyiJ T Willerson
Sep 12, 2000·Current Cardiology Reports·K M Channon, B H Annex
Jan 15, 2001·Current Cardiology Reports·J RutanenS Ylä-Herttuala
Jan 5, 2001·Current Cardiology Reports·D G Cable, H V Schaff
May 31, 2008·Expert Review of Cardiovascular Therapy·Shalini BhardwajSeppo Ylä-Herttuala
Jul 22, 2006·Expert Opinion on Biological Therapy·Peng H TanChristopher L H Chan
Jul 2, 2005·Expert Opinion on Investigational Drugs·C M Lynch
Mar 8, 2003·International Journal of Cardiovascular Interventions·Noel M CapliceDavid R Holmes
May 15, 2003·British Journal of Pharmacology·Kazunori ToyodaDonald D Heistad
May 16, 2006·Vascular Pharmacology·Vladimir BobekKatarina Kolostova
Jul 1, 1997·The Journal of Surgical Research·S LilleA W Clowes
Jul 29, 1999·The Journal of Surgical Research·J S MatsumuraW H Pearce
Feb 12, 2013·Molecular Pharmaceutics·Debbie GohAlexander M Seifalian
Dec 12, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·P Factor
Aug 3, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·S SinghJ Nemunaitis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.